Alumis (NASDAQ:ALMS - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.06), Zacks reports.
Alumis Stock Performance
ALMS traded down $0.04 on Wednesday, reaching $4.42. The company's stock had a trading volume of 730,652 shares, compared to its average volume of 743,050. The stock has a 50 day moving average of $3.54 and a two-hundred day moving average of $4.71. Alumis has a fifty-two week low of $2.76 and a fifty-two week high of $13.11.
Hedge Funds Weigh In On Alumis
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. New York State Common Retirement Fund boosted its holdings in Alumis by 173.7% in the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company's stock valued at $35,000 after purchasing an additional 7,467 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Alumis by 64.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company's stock valued at $77,000 after purchasing an additional 4,926 shares in the last quarter. Rhumbline Advisers boosted its holdings in Alumis by 21.7% in the first quarter. Rhumbline Advisers now owns 16,543 shares of the company's stock valued at $102,000 after purchasing an additional 2,949 shares in the last quarter. American Century Companies Inc. acquired a new position in Alumis in the second quarter valued at approximately $106,000. Finally, Jane Street Group LLC acquired a new position in Alumis in the first quarter valued at approximately $111,000.
Analyst Ratings Changes
A number of analysts have issued reports on ALMS shares. Wells Fargo & Company initiated coverage on shares of Alumis in a research note on Friday, July 25th. They set an "overweight" rating and a $17.00 price target on the stock. Guggenheim raised Alumis to a "buy" rating and set a $18.00 price objective for the company in a research report on Tuesday, June 10th. Oppenheimer lowered their price objective on Alumis from $26.00 to $25.00 and set an "outperform" rating for the company in a research report on Thursday, May 15th. Finally, HC Wainwright reissued a "buy" rating and set a $14.00 price objective on shares of Alumis in a research report on Friday, July 25th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Alumis has a consensus rating of "Buy" and an average target price of $19.80.
Check Out Our Latest Report on ALMS
Alumis Company Profile
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access